BIIB — Biogen Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Price data
- Price
- $248.41
- YTD price return
- +41.15%
- YTD total return
- +41.15%
- Market cap
- 36.7B
- Enterprise value
- 43.5B
- Shares outstanding
- 147.8M
- 52W low
- $151.83
- 52W high
- $258.78
- From 52W high
- -4.01%
- From 52W low
- +63.61%
- 52W range
- 90%$152–$259
- Beta
- 0.16
Volume
- Rel volume
- 0.52×
- 30D volume
- 1.3M
- 30D $ vol
- 308.3M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- none
- Insider net 1Y
- −$905K
Form 4 transactions by trade date, as filed; latest on file 2026-08-04.
Fundamentals
- Sales (ttm)
- 10.3B
- Sales/share
- $69.66
- EPS (ttm)
- $2.34
- FCF (ttm)
- 2.1B
- FCF/share
- $14.01
- Book value/share
- $128.01
- Net margin
- 3.37%
- ROE
- 1.84%
- ROA
- 1.08%
- Debt / equity
- 0.39×
- Current ratio
- 1.95
Growth (CAGR, ttm) · 10Y
- Sales
- +2.30%+1.00%-1.49%-1.03%
- Net income
- -78.42%-38.05%-25.81%-21.45%
- FCF
- -10.15%+24.94%-0.67%-4.91%
- Shares
- +0.76%+0.67%+0.13%-3.79%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -78.67%-38.47%-25.51%-18.31%
- Sales/share
- +1.53%+0.33%-1.62%+2.87%
- FCF/share
- -10.83%+24.11%-0.80%-1.16%
- Book value/share
- +3.14%+8.59%+12.51%+8.68%
- Price
- +58.54%-0.03%-2.27%-1.08%
- Total return
- +58.54%-0.03%-2.27%-1.08%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 106.0×
- P/OI (ttm)
- 15.6×
- Fwd P/E
- 15.3×
- P/S (ttm)
- 3.6×
- P/B (mrq)
- 1.9×
- P/FCF (ttm)
- 17.7×
- EV/EBITDA (fy)
- 26.6×
- EV/Sales (ttm)
- 4.2×
- FCF yield (ttm)
- 5.64%
- Buyback yield (realized, 1y)
- -0.76%
- Shareholder yield (realized, 1y)
- -0.76%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/E
- 100th
- P/OI
- 91st
- P/S
- 57th
- P/B
- 23rd
- P/FCF
- 68th
Bar = where today’s multiple sits in BIIB’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Fundamentals#
Operating income
5Y CAGR −11.2%10Y CAGR +5.1%YoY −37.3%EPS (diluted)
5Y CAGR −18.7%10Y CAGR −5.4%YoY n/mFree cash flow
5Y CAGR −11.6%10Y CAGR −4.6%YoY −51.0%TTM: operating cash flow $2.2B, capex −$176.4M
Q3 2026: operating cash flow $640.8M, capex −$40.4M
Shares (diluted)
5Y −8.8%10Y −36.4%YoY +0.5%Net income
5Y CAGR −20.2%10Y CAGR −9.6%YoY n/mAbout Biogen#
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and Friedreich’s ataxia, along with therapies and biosimilars used in specialized immunology and related areas. The company also advances medicines through its research and development programs, with a strong emphasis on neuroscience and immunology. Based in Cambridge, Massachusetts, Biogen serves patients and healthcare providers across multiple global markets through its commercial products and collaborations. Its role in the financial market is shaped by its concentration in specialty biopharmaceuticals, recurring demand for chronic-disease treatments, and continued activity in pipeline development and product commercialization.
Cambridge, MA·7,500 employees·Drug Manufacturers - General·biogen.com·As of Oct 28, 2026
Recent filings#
- Oct 28Earnings · Earnings release — EPS $2.62 vs $2.06 est. (+27.2%); revenue $2.80B (+11% y/y) 3.4%
- Jul 29Earnings · Earnings release — EPS $3.60 vs $3.04 est. (+18.4%); revenue $2.74B (+3% y/y) 1.8%
ETFs holding BIIB#
35 of the 193 ETFs ChartRow carries live hold BIIB. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 2.5% |
| XBI | SPDR S&P Biotech ETF | 1.0% |
| COWZ | Pacer US Cash Cows 100 ETF | 0.7% |
| XLV | Health Care Select Sector SPDR Fund | 0.6% |
| VOE | Vanguard Mid-Cap Value ETF | 0.6% |
| VHT | Vanguard Health Care ETF | 0.4% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.3% |
| VO | Vanguard Mid-Cap ETF | 0.3% |
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.43% | +1.45% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.15% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.73% | -0.40% |
| NVS | Novartis AG | +15.44% | +0.37% |
| TMO | Thermo Fisher Scientific Inc. | +5.82% | +2.64% |
| AMGN | Amgen Inc. | +14.30% | -0.03% |
